-
Something wrong with this record ?
A liquid chromatography - Tandem mass spectrometry method for determination of ocrelizumab in serum of patients with multiple sclerosis
P. Matlak, H. Brozmanova, P. Sistik, D. Moskorova, I. Kacirova, P. Hradilek, M. Grundmann
Language English Country Netherlands
Document type Journal Article
- MeSH
- Chromatography, Liquid methods MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use blood MeSH
- Humans MeSH
- Drug Monitoring methods MeSH
- Multiple Sclerosis * drug therapy blood MeSH
- Tandem Mass Spectrometry * methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Ocrelizumab is a second generation recombinant humanized IgG1 monoclonal antibody used for the treatment of multiple sclerosis that selectively target B cells expressing the CD20 antigen. This study aimed to develop and validate a UPLC-MS/MS method for quantification of ocrelizumab in human serum, which can be used in clinical applications for therapeutic drug monitoring. The analysis of ocrelizumab was performed using a bottom-up approach on a liquid chromatography coupled to tandem mass spectrometry detection. The method involved immunoglobulin precipitation with cold methanol followed by peptide digestion with trypsin. The resulting specific peptides were separated on an Acquity UPLC BEH C18 column at 55 °C using gradient elution. The method was validated according to European Medicines Agency (EMEA) guidelines and demonstrated intra- and inter-assay precision with coefficients of variation ranging from 1.6 % to 6.1 % and accuracies between 90.2 % and 107.2 %. Stability testing, including autosampler, long-term and freeze-thaw stability, showed no more than 15 % variation. The method was successfully applied to 169 patient samples, revealing ocrelizumab concentrations ranging from 0.5 to 21.8 mg/L in patients on 6-month dosing regimen and 20.5-65.0 mg/L in 16 patients receiving an initial two-week dose of 300 mg. The newly developed UPLC-MS/MS method met all criteria for accuracy, precision and stability, confirming its suitability for clinical use in monitoring ocrelizumab levels in multiple sclerosis patients.
Department of Neurology University Hospital Ostrava 17 listopadu 1790 5 Ostrava 70852 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002831
- 003
- CZ-PrNML
- 005
- 20250206103907.0
- 007
- ta
- 008
- 250121e20241028ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.talanta.2024.127111 $2 doi
- 035 __
- $a (PubMed)39486303
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Matlak, Patrik $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic. Electronic address: patrik.matlak@fno.cz
- 245 12
- $a A liquid chromatography - Tandem mass spectrometry method for determination of ocrelizumab in serum of patients with multiple sclerosis / $c P. Matlak, H. Brozmanova, P. Sistik, D. Moskorova, I. Kacirova, P. Hradilek, M. Grundmann
- 520 9_
- $a Ocrelizumab is a second generation recombinant humanized IgG1 monoclonal antibody used for the treatment of multiple sclerosis that selectively target B cells expressing the CD20 antigen. This study aimed to develop and validate a UPLC-MS/MS method for quantification of ocrelizumab in human serum, which can be used in clinical applications for therapeutic drug monitoring. The analysis of ocrelizumab was performed using a bottom-up approach on a liquid chromatography coupled to tandem mass spectrometry detection. The method involved immunoglobulin precipitation with cold methanol followed by peptide digestion with trypsin. The resulting specific peptides were separated on an Acquity UPLC BEH C18 column at 55 °C using gradient elution. The method was validated according to European Medicines Agency (EMEA) guidelines and demonstrated intra- and inter-assay precision with coefficients of variation ranging from 1.6 % to 6.1 % and accuracies between 90.2 % and 107.2 %. Stability testing, including autosampler, long-term and freeze-thaw stability, showed no more than 15 % variation. The method was successfully applied to 169 patient samples, revealing ocrelizumab concentrations ranging from 0.5 to 21.8 mg/L in patients on 6-month dosing regimen and 20.5-65.0 mg/L in 16 patients receiving an initial two-week dose of 300 mg. The newly developed UPLC-MS/MS method met all criteria for accuracy, precision and stability, confirming its suitability for clinical use in monitoring ocrelizumab levels in multiple sclerosis patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a tandemová hmotnostní spektrometrie $x metody $7 D053719
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $x krev $7 D061067
- 650 12
- $a roztroušená skleróza $x farmakoterapie $x krev $7 D009103
- 650 _2
- $a chromatografie kapalinová $x metody $7 D002853
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brozmanova, Hana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic
- 700 1_
- $a Sistik, Pavel $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic
- 700 1_
- $a Moskorova, Denisa $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic
- 700 1_
- $a Kacirova, Ivana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic
- 700 1_
- $a Hradilek, Pavel $u Department of Neurology, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava, 70852, Czech Republic; Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava, 703 00, Czech Republic
- 700 1_
- $a Grundmann, Milan $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava, Czech Republic; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790/5, 708 52, Ostrava, Czech Republic
- 773 0_
- $w MED00004484 $t Talanta $x 1873-3573 $g Roč. 283 (20241028), s. 127111
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39486303 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103903 $b ABA008
- 999 __
- $a ok $b bmc $g 2262932 $s 1238838
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 283 $c - $d 127111 $e 20241028 $i 1873-3573 $m Talanta $n Talanta $x MED00004484
- LZP __
- $a Pubmed-20250121
